Skip to main content
Premium Trial:

Request an Annual Quote

Paul Grint, Scott Greer, Andre Hoekema, Bruce Kimmel, David Weber


Illumina has appointed Paul Grint to its board of directors. Grint is currently senior vice president and chief medical officer of Zephyr Sciences, a biopharmaceutical company. He received his MD from the University of London, St. Bartholomew's Hospital Medical College.

Illumina also announced the April 12 resignation of director Scott Greer, chairman of Abgenics, an Illumina director since May 2001.

Galapagos has appointed Andre Hoekema as managing director of Galadeno, Galapagos' services unit. Galadeno performs target discovery using adenoviral siRNA technologies.

Hoekema, 47, joins Galapagos from Invitrogen, where he served as the managing director of corporate development in Europe.

Ambrx has appointed Bruce Kimmel as vice president of therapeutic applications. He obtained his PhD in biochemistry from the University of California, Berkeley, and conducted postdoctoral work at UCSF.

Stratagene has hired David Weber as its new senior vice president of marketing. He comes to Stratagene from GE Healthcare, where he was president, Region Americas, where he managed sales for the United States, Canada, and Latin America. Weber earned a BS in biochemistry from Rutgers University.

Filed under

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.